Recorded Webinar - 12 May 2026
Most Favoured Nation (MFN) pricing has quickly become one of the most talked-about developments in US healthcare policy. But beyond the headlines, what does it actually mean for global pricing and, more importantly, for launch planning and execution?
In this 45-minute webinar, experts from Access Infinity cut through the noise to explore what MFN could mean in practice. Drawing on insights from both US and European markets, they highlight where the real risks lie for global teams and outline what actions you can take now to stay ahead.
Watch the recording and get a clearer view of how different policy scenarios could play out and what they mean for your pricing across markets, launch sequencing, and overall strategy.
The three MFN models
MFN is not a single policy. Three models are being introduced, each aimed at a different part of the US system.
| Model | Channel | Status |
|---|---|---|
| GENEROUS | Medicaid | Voluntary |
| GLOBE | Medicare Part B, physician-administered drugs | Mandatory |
| GUARD | Medicare Part D, retail and pharmacy medicines | Mandatory |
The latest White House guidance indicates that MFN would also apply across the private insurance market, not only government programmes.
Four possible futures
Rather than planning for a single outcome, plan for scenarios.
MFN softens. The initial pressure diminishes and the system stabilises.
Partial implementation. MFN exists but stays contained to certain channels or products. This is where it sits today.
Expanded MFN. Broader application and meaningful pressure on US pricing, particularly if it is codified into law.
Structural reset. MFN alongside PBM transparency fundamentally changes how pricing works across the system.
What it changes for launch strategy
MFN acts as a stress test on how robust a launch strategy really is.
Launch price anchoring. Early price decisions, particularly in Europe, set the ceiling for what is achievable in the US, leaving far less room to adjust after launch.
Sequencing. Launching early in low-price markets creates a downward cascade through international reference pricing and MFN. Speed now trades off against price protection.
Evidence. Greater reliance on HTA-driven markets to establish value means stronger comparative and economic evidence is needed earlier in development.
Lifecycle and portfolio. Existing brands are exposed through reference baskets, not only new launches.
What is already happening
EU launches fell by 35% after the first MFN policy was introduced.
Early access applications in France dropped from 25 in 2024 to 10 in 2025.
More than 90% of drugs approved in 2025 that launched first in the US are still not available outside the US.
Manufacturers are tightening international price corridors, and making greater use of managed entry agreements and outcomes-based contracts to avoid disclosing lower list prices.
What global teams are doing about it
Moving pricing and launch decisions from local optimisation to global coordination.
Aligning global pricing, US and ex-US launch strategy, medical and HEOR much earlier.
Prioritising Europe and ex-US markets in evidence planning, to protect prices more widely.
Building scenario models that test launch sequence assumptions and price corridor compression.
Continue your learning about Market Access and Payers
If you’d like to learn more from Louisa and Megan, CELforPharma also offers two 1-day, hands-on courses that will get you up the learning curve quickly!
Understanding Pharma Market Access in the US
With Dr Nick Proctor & Louisa Oliver Byrne
Understanding Pharma Market Access & Payers in Europe
With Dr Nick Proctor & Megan O'Brien
Don’t miss future CELforPharma webinars
Subscribe to our newsletter to:
- Receive invitations to upcoming educational webinars
- Stay on top of the latest expert insights
- Get updates on our courses and training programmes